STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0578	A. BUILDING: _____ B. WING _____	05/07/2024

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
FREEPORT PLACE	4 OLD COUNTY RD FREEPORT, ME 04032

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
P 000	Initial Comments On 5/6/24 and 5/7/24, onsite visits were made at Freeport Place, for the purpose of completing the state re-licensure survey. It was determined that Freeport Place was not in substantial compliance with 10/144, Chapter 113- Regulations Governing the Licensing and Functioning of Assistive Housing Programs-Level IV, Private Non-Medical Institutions.	P 000		
P 304	7.1.2 Medications and Treatments No injectable medications may be administered by an unlicensed person, with the exception of bee sting kits and insulin. This STANDARD is not met as evidenced by: Based on record review and interview, the facility failed to ensure that injectable medications (exclusive of bee sting kits and insulin), were not administered by an unlicensed person, for 2 of 3 residents reviewed (#1, #2). Findings: Review of Resident #1's clinical record noted a diagnosis of Type 2 Diabetes Mellitus. A review of licensed provider orders noted an order, dated 1/23/24, for Semaglutide 2 mg/3 ml pen (milligrams per milliliter), give 0.25 mg per injection once weekly. In addition, a previous order was noted, dated 1/11/24, for Trulicity 0.75 mg/0.5 ml, inject 1 dose subcutaneously one time a day every Thursday. This order was discontinued on 1/22/24. The orders did not include that a CRMA (certified residential medication aide) could administer the medication nor any additional instructions of when to hold the medication, monitoring of side effects, or symptoms to report to the provider.	P 304		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0578	A. BUILDING: _____ B. WING _____	05/07/2024

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
FREEPORT PLACE	4 OLD COUNTY RD FREEPORT, ME 04032

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
P 304	Continued From page 1 Review of Resident #2's clinical record noted a diagnosis of Type 2 Diabetes Mellitus. A review of licensed provider orders, dated 1/11/24, noted an order for Trulicity 0.75mg/0.5 ml, inject 1 dose subcutaneously one time a day every Tuesday. The orders did not include that a CRMA (certified residential medication aide) could administer the medication nor any additional instructions of when to hold the medication, monitoring of side effects, or symptoms to report to the provider. The Food and Drug Administration's website, posted the following on 1/10/24, "Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the GLP-1 hormone that is released in the gastrointestinal tract in response to eating. One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar)." The manufacturer's prescribing information stated Trulicity (generic name dulaglutide) is a "glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of diabetes and stimulates glucose-dependent insulin secretion and reduces glucagon secretion. Trulicity is a non-insulin option that helps the body release the insulin it's already making." On 5/6/24 at 11:20 a.m., in an interview with the Resident Care Director (RCD) and the Lead CRMA, the surveyor confirmed that these medications were administered by CRMA staff because they are given by the subcutaneous route. The RCD confirmed that staff had not received specific training regarding the use of these medications.	P 304		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0578	A. BUILDING: _____ B. WING _____	05/07/2024

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
FREEPORT PLACE	**4 OLD COUNTY RD FREEPORT, ME 04032**

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
P 304	Continued From page 2 The surveyor discussed with the RCD and Lead CRMA that administering injectable medications besides insulin or epinephrine (bee sting kits) is outside of the scope of practice for a CRMA and is not permitted under current rules and regulations.	P 304		